← Eichor
Condition: Egfr Tki Resistant Mutation Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Egfr Tki Resistant Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
Phase 1/Phase 2 · 1 location(s) · China Medical University Hospital · NCT06071013Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06363734A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT01994057Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Adv
Phase N/A · 1 location(s) · Second Xiangya Hospital of Central South University · NCT05598528A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Phase 1/Phase 2 · 42 location(s) · BlossomHill Therapeutics · NCT06706076
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.